{"organizations": [], "uuid": "3979f1920011f7fb1caf43498100e6fe2f748840", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180412.html", "section_title": "Archive News &amp; Video for Thursday, 12 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-argenx-to-receive-third-preclinica/brief-argenx-to-receive-third-preclinical-milestone-payment-from-collaboration-with-leo-pharma-idUSFWN1RP00U", "country": "US", "domain_rank": 408, "title": "BRIEF-Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.064, "site_type": "news", "published": "2018-04-12T13:14:00.000+03:00", "replies_count": 0, "uuid": "3979f1920011f7fb1caf43498100e6fe2f748840"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-argenx-to-receive-third-preclinica/brief-argenx-to-receive-third-preclinical-milestone-payment-from-collaboration-with-leo-pharma-idUSFWN1RP00U", "ord_in_thread": 0, "title": "BRIEF-Argenx To Receive Third Preclinical Milestone Payment From Collaboration With Leo Pharma", "locations": [], "entities": {"persons": [{"name": "argenx", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "leo pharma", "sentiment": "negative"}, {"name": "cta", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "gdynia newsroom", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 12 (Reuters) - ARGENX:\n* TO RECEIVE THIRD PRECLINICAL MILESTONE PAYMENT FROM COLLABORATION WITH LEO PHARMA - MILESTONE ASSOCIATED WITH CTA APPROVAL FOR ARGX\n* AS PART OF AGREEMENT, ARGENX HAS GRANTED LEO PHARMA AN EXCLUSIVE OPTION TO OBTAIN A WORLDWIDE, EXCLUSIVE LICENSE TO ARGX-112 PROGRAM,\n* ARGX-112 PROGRAM AIMS TO DEVELOP AND COMMERCIALIZE LICENSED PRODUCTS FOR INFLAMMATORY SKIN DISORDERS\n* MAY RECEIVE FURTHER REGULATORY AND CLINICAL MILESTONE PAYMENTS UP TO APPROX. EUR 100MM AS WELL AS ROYALTIES ON NET SALES OF ANY PRODUCT Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-12T13:14:00.000+03:00", "crawled": "2018-04-13T17:52:50.013+03:00", "highlightTitle": ""}